Even though at different extend, increasing concentrations of each EO displayed a similar ability in significantly reducing the viability of both BRAF wild type/NRAS mutant (Sbcl1, ME4405), BRAF wild type/NRAS wild type (ME1007), and BRAF mutant/NRAS wild type (M14, A375, LOX IMVI) melanoma cells (Fig. 2a–f, Fig. S1c), thus indicating the absence of relevance of BRAF or NRAS status in the sensitivity to EOs. The gene discussed is BRAF; the disease is melanoma.